HERCULES, CA and DUNDEE, SCOTLAND--(Marketwire - 10/13/10) - Bio-Rad Laboratories, Inc. (NYSE:BIO - News) and (NYSE:BIO.B - News), a multinational manufacturer and distributor of life science research and clinical diagnostics products, and Axis-Shield plc (LSE:ASD - News) (OSE:ASD - News), an international and innovative in vitro diagnostics (IVD) company, today announced the U.S. Food and Drug Administration (FDA) clearance and U.S. launch of Bio-Rad’s BioPlex® 2200 Anti-CCP test for the early detection of rheumatoid arthritis. The assay, which runs on Bio-Rad’s BioPlex® 2200 system, measures anti-CCP (anti-cyclic citrullinated peptide antibodies), a novel marker that has been shown to have superior specificity in the diagnosis of rheumatoid arthritis. The BioPlex 2200 Anti-CCP assay is based on Axis-Shield’s proprietary anti-CCP technology and was launched in territories outside the U.S. earlier in 2010.
